---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-044828"
form_type: "8-K"
ticker: "ALLO"
cik: "0001737287"
company_name: "Allogene Therapeutics, Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:56:36.931481+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Allogene reports patent infringement lawsuit against licensor Cellectis by Factor Bioscience

## Summary
- Factor Bioscience filed a complaint in Delaware against Cellectis and AstraZeneca on Sept 26, 2025, alleging TALEN gene-editing patent infringement.
- Allogene relies on Cellectis's TALEN technology for allogeneic CAR T candidates including cema-cel and ALLO-316.
- Cellectis notified Allogene on October 6, 2025, and intends to vigorously defend against the claims.
- Factor may also assert direct claims against Allogene as a commercial user of the disputed technology.

## SEC filing metadata
- accession: 0001628280-25-044828
- form_type: 8-K
- ticker: ALLO
- cik: 0001737287
- company_name: Allogene Therapeutics, Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737287/000162828025044828/0001628280-25-044828-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737287/000162828025044828/allo-20250926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-044828
- JSON: https://secwatch.observer/filing/0001628280-25-044828.json
- Plain text: https://secwatch.observer/filing/0001628280-25-044828.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.